Literature DB >> 18335262

Differential expression of alpha-synuclein, parkin, and synphilin-1 isoforms in Lewy body disease.

Katrin Beyer1, Montserrat Domingo-Sàbat, Jordi Humbert, Cristina Carrato, Isidro Ferrer, Aurelio Ariza.   

Abstract

Alpha-synuclein, parkin, and synphilin-1 are proteins mainly involved in the pathogenesis of Lewy body (LB) diseases. mRNAs of all three undergo alternative splicing, so that the existence of various isoforms has been described. Since increasing evidence supports the importance of differential isoform-expression changes in disease development, we have established isoform-expression profiles in frontal cortices of LB disease brains in comparison with those of Alzheimer disease (AD) and control frontal cortices. The differential expression of four alpha-synuclein, seven parkin, and four synphilin-1 isoforms was ascertained by the use of isoform-specific primers and relative expression analysis with SybrGreen and beta-actin as an internal standard. The establishment of isoform-expression profiles revealed that these are disease specific. Moreover, isoform-expression deregulation of mainly one gene in each disease could be observed. All four alpha-synuclein isoforms were affected in the case of the pure form of dementia with LB, most parkin transcript variants in common LB disease, and all synphilin-1 isoforms in Parkinson disease. Only minor involvement was detected in AD. Finally, the existence of a proprietary isoform-expression profile in common LB disease indicates that this disease develops as a result of its own molecular mechanisms, and so, at the molecular level, it does not exactly share changes found in pure dementia with LB and AD. In conclusion, isoform-expression profiles in LB diseases represent additional evidence for the direct involvement of isoform-expression deregulation in the development of neurodegenerative disorders.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18335262     DOI: 10.1007/s10048-008-0124-6

Source DB:  PubMed          Journal:  Neurogenetics        ISSN: 1364-6745            Impact factor:   2.660


  48 in total

Review 1.  Dementia with Lewy bodies: an emerging disease.

Authors:  Doug Neef; Anne D Walling
Journal:  Am Fam Physician       Date:  2006-04-01       Impact factor: 3.292

2.  Parkin and synphilin-1 isoform expression changes in Lewy body diseases.

Authors:  Jordi Humbert; Katrin Beyer; Cristina Carrato; José L Mate; Isidro Ferrer; Aurelio Ariza
Journal:  Neurobiol Dis       Date:  2007-03-27       Impact factor: 5.996

3.  Evidence of oxidative stress in the neocortex in incidental Lewy body disease.

Authors:  Esther Dalfó; Manuel Portero-Otín; Victoria Ayala; Anna Martínez; Reinald Pamplona; Isidre Ferrer
Journal:  J Neuropathol Exp Neurol       Date:  2005-09       Impact factor: 3.685

4.  Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease.

Authors:  K K Chung; Y Zhang; K L Lim; Y Tanaka; H Huang; J Gao; C A Ross; V L Dawson; T M Dawson
Journal:  Nat Med       Date:  2001-10       Impact factor: 53.440

5.  Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase.

Authors:  H Shimura; N Hattori; S i Kubo; Y Mizuno; S Asakawa; S Minoshima; N Shimizu; K Iwai; T Chiba; K Tanaka; T Suzuki
Journal:  Nat Genet       Date:  2000-07       Impact factor: 38.330

6.  Early alpha-synuclein lipoxidation in neocortex in Lewy body diseases.

Authors:  Esther Dalfó; Isidre Ferrer
Journal:  Neurobiol Aging       Date:  2006-12-12       Impact factor: 4.673

7.  Tissue-dependent alternative splicing of mRNA for NACP, the precursor of non-A beta component of Alzheimer's disease amyloid.

Authors:  K Uéda; T Saitoh; H Mori
Journal:  Biochem Biophys Res Commun       Date:  1994-12-15       Impact factor: 3.575

8.  Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions.

Authors:  S Engelender; Z Kaminsky; X Guo; A H Sharp; R K Amaravi; J J Kleiderlein; R L Margolis; J C Troncoso; A A Lanahan; P F Worley; V L Dawson; T M Dawson; C A Ross
Journal:  Nat Genet       Date:  1999-05       Impact factor: 38.330

Review 9.  The etiopathogenesis of Parkinson disease and suggestions for future research. Part I.

Authors:  Irene Litvan; Glenda Halliday; Mark Hallett; Christopher G Goetz; Walter Rocca; Charles Duyckaerts; Yoav Ben-Shlomo; Dennis W Dickson; Anthony E Lang; Marie-Francoise Chesselet; William J Langston; Donato A Di Monte; Thomas Gasser; Theo Hagg; John Hardy; Peter Jenner; Eldad Melamed; Richard H Myers; Davis Parker; Donald L Price
Journal:  J Neuropathol Exp Neurol       Date:  2007-04       Impact factor: 3.685

10.  Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop.

Authors:  Ian G McKeith
Journal:  J Alzheimers Dis       Date:  2006       Impact factor: 4.472

View more
  30 in total

Review 1.  Understanding protein non-folding.

Authors:  Vladimir N Uversky; A Keith Dunker
Journal:  Biochim Biophys Acta       Date:  2010-02-01

2.  DEGAS: de novo discovery of dysregulated pathways in human diseases.

Authors:  Igor Ulitsky; Akshay Krishnamurthy; Richard M Karp; Ron Shamir
Journal:  PLoS One       Date:  2010-10-19       Impact factor: 3.240

3.  The effect of SNCA 3' region on the levels of SNCA-112 splicing variant.

Authors:  Jeanette J McCarthy; Colton Linnertz; Laura Saucier; James R Burke; Christine M Hulette; Kathleen A Welsh-Bohmer; Ornit Chiba-Falek
Journal:  Neurogenetics       Date:  2010-11-03       Impact factor: 2.660

Review 4.  Structural variants in SNCA gene and the implication to synucleinopathies.

Authors:  Ornit Chiba-Falek
Journal:  Curr Opin Genet Dev       Date:  2017-03-02       Impact factor: 5.578

5.  Proteomic Analysis of Parkin Isoforms Expression in Different Rat Brain Areas.

Authors:  Agata Grazia D'Amico; Grazia Maugeri; Rita Reitano; Sebastiano Cavallaro; Velia D'Agata
Journal:  Protein J       Date:  2016-10       Impact factor: 2.371

6.  New brain-specific beta-synuclein isoforms show expression ratio changes in Lewy body diseases.

Authors:  Katrin Beyer; Ana M Munoz-Marmol; Carolina Sanz; Ruth Marginet-Flinch; Isidro Ferrer; Aurelio Ariza
Journal:  Neurogenetics       Date:  2011-12-29       Impact factor: 2.660

7.  Transcript expression levels of full-length alpha-synuclein and its three alternatively spliced variants in Parkinson's disease brain regions and in a transgenic mouse model of alpha-synuclein overexpression.

Authors:  Jesse R McLean; Penelope J Hallett; Oliver Cooper; Michael Stanley; Ole Isacson
Journal:  Mol Cell Neurosci       Date:  2011-12-06       Impact factor: 4.314

8.  Localization of synucleins in the mammalian cochlea.

Authors:  O Akil; C M Weber; S N Park; N Ninkina; V Buchman; L R Lustig
Journal:  J Assoc Res Otolaryngol       Date:  2008-07-30

Review 9.  Dysfunction of two lysosome degradation pathways of α-synuclein in Parkinson's disease: potential therapeutic targets?

Authors:  Tian-Fang Jiang; Sheng-Di Chen
Journal:  Neurosci Bull       Date:  2012-09-08       Impact factor: 5.203

Review 10.  α-Synuclein posttranslational modification and alternative splicing as a trigger for neurodegeneration.

Authors:  Katrin Beyer; Aurelio Ariza
Journal:  Mol Neurobiol       Date:  2012-08-25       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.